Oxaliplatin sensitizes drug-resistant colon cancer cell lines to tumor necrosis factorrelated apoptosis inducing ligand (TRAIL), a death receptor ligand that is selective for cancer cells. We investigated the molecular mechanisms by which oxaliplatin sensitizes cancer cells to TRAIL-induced apoptosis. METHODS: We incubated the colon cancer cell lines HT29 and V9P, which are resistant to TRAIL, with TRAIL or with oxaliplatin for 2 hours, followed by TRAIL. Annexin V staining was used to measure apoptosis; RNA silencing and immunoblot experiments were used to study the roles of apoptosis-related proteins. Site-directed mutagenesis experiments were used to determine requirements for phosphorylation of Bcl-xL; coimmunoprecipitation experiments were used to analyze the interactions among Bcl-xL, Bax, and Bak, and activation of Bax. RESULTS: Oxaliplatin-induced sensitivity to TRAIL required activation of the mitochondrial apoptotic pathway; reduced expression of Bax, Bak, and caspase-9, and stable overexpression of Bcl-xL, reduced TRAIL-induced death of cells incubated with oxaliplatin. Mitochondrial priming was induced in cells that were sensitized by oxaliplatin and required signaling via c-Jun N-terminal kinase and phosphorylation of Bcl-xL. Mimicking constitutive phosphorylation of Bcl-xL by site-directed mutagenesis at serine 62 restored sensitivity of cells to TRAIL. Co-immunoprecipitation experiments showed that oxaliplatin-induced phosphorylation of Bcl-xL disrupted its ability to sequestrate Bax, allowing Bax to interact with Bak to induce TRAIL-mediated apoptosis. CONCLUSIONS: Oxaliplatin facilitates TRAIL-induced apoptosis in colon cancer cells by activating c-Jun N-terminal kinase signaling and phosphorylation of Bcl-xL. Oxaliplatin-induced sensitivity to TRAIL might be developed as an approach to cancer therapy.
C olon cancer is the second leading cause of cancerrelated deaths in Western countries. Chemotherapy is the treatment of choice for patients with recurrent colon tumors, but despite the introduction of several novel anticancer agents, almost 50% of patients die because of disease progression. It is therefore of interest to develop new therapeutic strategies.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent because of its ability to induce apoptosis selectively in cancer cells. 1 TRAIL binds to the cell surface death receptors (DR)4 and DR5 to trigger the extrinsic apoptotic pathway, mainly through the activation of the pro-apoptotic initiator caspase-8. 2 In type I cells, active caspase-8 induces the cleavage of the downstream effector caspase-3, which ultimately leads to apoptosis. 3 By contrast, in type II cells, apoptosis requires an amplification loop, generally afforded by the intrinsic (mitochondrial) cell death pathway. 4 This pathway is tightly regulated by the Bcl-2 family through complex interactions that dictate the integrity of the outer mitochondrial membrane. 5 The BH3-only pro-apoptotic proteins (Bid, Bad, Bim, Noxa, Puma, and so forth) act as initiators of the intrinsic apoptotic pathway, whereas the multidomain pro-apoptotic proteins Bax and Bak act as essential mediators of mitochondrial permeability. 5 The anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-xL, and Mcl-1) inhibit apoptosis by binding to these pro-apoptotic members, thus neutralizing their activity. Overexpression of anti-apoptotic Bcl-2 family proteins is one of the major causes of TRAIL resistance. 6 The function of Bcl-xL can be regulated by transcriptional control and/or post-transcriptional modifications. Emerging evidence indicates that Bcl-xL phosphorylation may regulate its antiapoptotic functions. Multiple kinases, including c-Jun N-terminal kinase (JNK), have been proposed to mediate the phosphorylation of Bcl-xL, 7, 8 but the functional role of this phosphorylation remains unknown.
Combinations of TRAIL with chemotherapeutic agents, including oxaliplatin, have been reported to generate synergistic antitumor responses in several human tumor types. 9, 10 Oxaliplatin, a third-generation platinum agent and usual chemotherapy agent for colon cancer, is thought to trigger cell death mainly by inducing platinum-DNA adducts, and appears to block DNA replication more effectively than other platinum compounds such as cisplatin. 11 However, scarce data are available regarding the signaling pathways activated by oxaliplatin. The molecular basis of the synergy between chemotherapeutic drugs and TRAIL remains elu-sive, complex, cell type-dependent, and depends on the specific drug, its concentration, and route of administration. By using short exposure time for oxaliplatin pretreatment and subsequent stimulation with TRAIL, we previously showed that oxaliplatin and TRAIL acted synergistically by inducing apoptosis in TRAIL-resistant cancer cell lines. 12 We show here that oxaliplatin induces Bcl-xL phosphorylation at the serine 62 (S62) residue in a JNK-dependent manner. Phosphorylation of Bcl-xL in turn induces the release of free Bax, allowing the activation of the mitochondrial pathway and thus activation of the apoptotic program after TRAIL stimulation.
Materials and Methods
For details see the online Supplementary Material and Methods section.
Cell Culture and Drug Treatment
Human colon cancer cell lines V9P were a gift from Dr R. Hamelin (INSERM U762, France) and HT29 were from American Type Culture Collection. A fresh solution of oxaliplatin (Eloxatin, 5 mg/mL; Sanofi Aventis) was added to adherent cells for 2 hours, removed, and replaced with fresh medium alone or with medium containing recombinant human TRAIL (Peprotech 50 g/mL; Figure 1 ).
Chemicals and Antibodies
JNK inhibitor (SP600125) was from Calbiochem. Annexin V-fluorescein isothiocyanate and propidium iodide (PI) were from AbCys SA, and Annexin V-antigenpresenting cell was provided by Becton-Dickinson. RIPA Lysis Buffer Kit was provided by Santa Cruz Biotechnology. Primary antibodies for the following proteins were from Cell Signaling Technology: caspase-8, caspase-9, caspase-3, Bid, cytochrome c, Cox IV, Mcl-1, Bcl-2, Bcl-xL, and phosphorylated JNK; from Epitomics for Bax and Bak proteins, from Santa Cruz Biotechnology for Bax 2D2 and S62 phosphorylated Bcl-xL, from BD Pharmingen for Bax 6A7, and from Sigma for ␣-tubulin.
Annexin V Staining and Flow Cytometry
Cells were stained with Annexin V and PI according to the manufacturer's instructions (AbCys SA), and analyzed with a FACScanto II flow cytometer (BD BectonDickinson). Apoptotic cell percentage corresponded to Annexin V(ϩ)/PI(Ϫ) cells.
Western Blot Analysis
For immunoblotting, whole-cell extracts were prepared using RIPA buffer according to the manufacturer's instructions (Santa Cruz Biotechnology). Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred to a polyvinylidene difluoride membrane (Bio-Rad) by electroblotting. The antigen-antibody complexes were visualized using a chemiluminescence method (Covalab). Quantification was performed using a Bio-Rad imaging system.
Cell Fractionation
Mitochondrial and cytosolic fractions were prepared according to the manufacturer's instructions (Pierce Biotechnology). Equal amounts of proteins were subjected to electrophoresis and immunoblot analysis as described earlier.
Phosphatase Treatment
After cell lysis, lysates were clarified by centrifugation (14,000 rpm, 15 minutes at 4°C), and divided into 2 equal aliquots. One aliquot was treated with 10 units of Calf Alkaline Phosphatase (Roche Diagnostics) and the other aliquot was mock-treated.
Small Interfering RNA Transfection
Small interfering RNA (siRNA) pool consisting of 4 siRNAs specific for each protein (ON-TARGET plus smart pool siRNAs; Dharmacon RNAi Technologies) were used to knock down caspase-8 (L-003466-00), caspase-3 (L-004307-00), caspase-9 (L-003309-00), Bax (L-003308-01), Bak (L-003305-00), and Bcl-xL (L-003454-00). For JNK silencing we used SignalSilence SAPK/JNK siRNA kit (Cell Signaling Technology), which provided 2 specific siRNAs for JNK. Control cells were transfected with a nontargeting siRNA (D-001206-13-05; Dharmacon). siRNAs were transfected at a final concentration of 100 nmol/L for 72 hours with DharmaFECT 4 following the manufacturer's protocols.
Construction of the Bcl-xL Phosphorylation Mutant
Substitution of S62 to asparagine (S62D) or alanine (S62A) into the pMIGR-BclXL-GFP retroviral plasmid was performed by polymerase chain reaction using the following specific oligonucleotides (Eurogentec): S62D sense: GGC-ACC-TGG-CAG-ACG-ACC-CCG-CGG-TGA-ATG; S62D antisense:  CAT-TCA-CCG-CGG-GGT-CGT-CTG-CCA-GGT-GCC; S62A  sense: GCA-CCT-GGC-AGA-CGC-CCC-CGC-GGT-GAA-T; S62A antisense: ATT-CAC-CGC-GGG-GGC-GTC-TGC-CAG-GTG-C. Mutations in the plasmids were checked by DNA sequencing (Beckman Coulter Genomics).
Retrovirus Production and Cell Transduction
Generation of retroviruses has been described previously. 13 HT29 cells were transduced for 16 hours with 
Immunoprecipitation
Briefly, cells were lysed in CHAPS lysis buffer (150 mmol/L sodium chloride, 10 mmol/L HEPES, pH 7.4, and 1.0% Chaps) with freshly added proteases and phosphatase inhibitors (Santa Cruz Biotechnology) and immunoprecipitated with ExactaCruz product (Santa Cruz Biotechnology), thereby bypassing any signal caused by immunoglobulin G heavy and light chains of the IP antibody and following the manufacturer's guidelines.
Statistical Analysis
All data are summarized as mean Ϯ standard error of the mean of at least 3 separate experiments. The Student t test was used to compare experimental with control groups. A P value of less than .05 was considered statistically significant.
Results

Oxaliplatin Sensitizes HT29 and V9P Colon Cancer Cells to TRAIL-Induced Apoptosis
HT29 and V9P colon cancer cells were pretreated with their median inhibitory concentration of oxaliplatin (IC 50oxaliplatin ) (219.05 mol/L and 19.19 mol/L, respectively) for 2 hours, then treated with 2 nonapoptotic doses of TRAIL (5 and 10 ng/mL) for 6 hours. HT29 and V9P cells were both highly resistant to oxaliplatin and TRAIL-induced apoptosis as single treatments (Figure 2A ). By contrast, the oxaliplatin/TRAIL combination significantly induced apoptosis in HT29 and V9P cells. Interestingly, when treating cells with TRAIL before oxaliplatin, the percentage of apoptotic cells did not increase significantly ( Supplementary  Figure 1) , indicating that oxaliplatin pretreatment potentiated TRAIL-induced apoptosis. Western blot analysis revealed that the oxaliplatin/TRAIL combination greatly enhanced caspase-8 and caspase-3 activation ( Figure 2B ). The increased caspase-8 activity after combined treatment was associated with cleavage of its substrate Bid, as indicated by a decreased intensity of the native 22-kilodalton form (Sup- plementary Figure 2 ). Interestingly, caspase-8 silencing only slightly decreased the percentage of oxaliplatin/TRAIL-induced apoptotic cells in both cell lines, in contrast to caspase-3 knockdown ( Figure 2C and Supplementary Figure  3A and B). These results indicate that oxaliplatin pretreatment sensitizes resistant colon cancer cells to TRAIL in a caspase-3-dependent but caspase-8 -independent manner.
Oxaliplatin/TRAIL-Induced Apoptosis Is Controlled Predominantly by the Mitochondrial Pathway
The oxaliplatin/TRAIL combination, but not single treatments, promoted cytochrome c release from the mitochondria into the cytosol ( Figure 3A) . Accordingly, Figure 3B shows that only combined treatments led to caspase-9 activation. Interestingly, inhibiting caspase-9 expression impaired the oxaliplatin/TRAIL-induced apoptosis in both cell lines ( Figure 3C and Supplementary Figure 3C ). Moreover, caspase-9 silencing significantly reduced oxaliplatin/TRAILinduced caspase-8 processing ( Figure 3D ). This result indicates that caspase-8 activation occurs downstream of caspase-9. In addition, Bax silencing in HT29 cells, and Bax and Bak silencing in V9P cells, significantly reduced oxaliplatin/TRAIL-induced apoptosis ( Figure 3E and Supplementary Figure 3D and E). Collectively, these results highlight the central role of the mitochondrial apoptotic pathway in oxaliplatin/TRAIL-induced apoptosis. HT29 and V9P cells were treated with oxaliplatin (IC 50 , 2 h), then TRAIL (10 ng/mL, 2 h), and after that Western blot analysis was performed for (A) cytochrome c release and (B) caspase-9 activation. Fraction purity and protein loading were assessed by Cox IV and ␣-tubulin blotting, respectively. HT29 and V9P cells were transfected with siRNA-mediating silencing of (C and D) caspase-9 or (E) Bax and Bak or nontargeting siRNAs (100 nmol/L) for 72 hours, and then treated with oxaliplatin (IC 50 , 2 h) then TRAIL (10 ng/mL, 6 h). After treatments, (C and E) apoptotic cell percentage corresponding to Annexin V(ϩ)/PI(Ϫ) cells was measured by flow cytometry analysis and (D) caspase-8 and caspase-9 cleavage was assessed by Western blot analysis. Data reflect mean Ϯ standard error of the mean (n ϭ 3). *P Ͻ .05; **P Ͻ .01 comparing specific targeting siRNAs with nontargeting siRNA.
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Oxaliplatin Induces Bcl-xL Phosphorylation Figure 4A shows that the total amounts of antiapoptotic members of the Bcl-2 family were unchanged after exposure to oxaliplatin and/or TRAIL. However, a slower migrating Bcl-xL band after incubation of cells with the oxaliplatin/TRAIL combination appeared in both cell lines. In vitro phosphatase treatment of protein extracts obtained from HT29 cells completely abolished the slow migrating band, indicating that this post-translational modification could correspond to a phosphorylated form of Bcl-xL (Supplementary Figure  4A) . Indeed, the use of a specific antibody recognizing the S62 phosphorylated form of Bcl-xL indicated that oxaliplatin induced the phosphorylation of Bcl-xL at S62 in both cell lines ( Figure 4B ). Oxaliplatin-induced Bcl-xL phosphorylation was maintained after TRAIL treatment ( Figure 4B ). Moreover, Bcl-xL siRNA restored the sensitivity of HT29 and V9P cells to TRAIL-induced apoptosis ( Figure 4C and Supplementary Figure 3F ). Of note, the sensitizing effect of Bcl-xL silencing was comparable with that obtained after oxaliplatin pretreatment ( Figure 4C ). This finding suggests that oxaliplatin-induced Bcl-xL phosphorylation may decrease Bcl-xL anti-apoptotic activity, thus promoting TRAILinduced apoptosis.
Oxaliplatin-Induced Bcl-xL Phosphorylation and Sensitization to TRAIL Require JNK Activation
Phosphorylation of Bcl-xL has been reported to be mediated by several kinases, including JNK, in response to chemotherapeutic agents. 8, 14, 15 Although TRAIL alone had no significant effect, oxaliplatin induced a rapid and prolonged JNK phosphorylation, the activation of which appeared to be strengthened by the combined treatment associating TRAIL ( Figure 5A ). As shown in Figure 5B , SP600125 (a specific JNK inhibitor) significantly reduced oxaliplatin/TRAIL-induced apoptosis in both cell lines. Moreover, JNK silencing significantly reduced apoptosis level in both cell lines ( Figure 5C ), indicating that the JNK pathway was crucial for oxaliplatin/TRAIL-induced apoptosis. We hypothesized that JNK may mediate oxaliplatin/TRAIL-induced apoptosis by targeting Bcl-xL. If so, the observed inhibitory effect of SP600125 on oxaliplatin/ TRAIL-induced apoptosis should not be observed in cells with reduced expression of Bcl-xL. Indeed, SP600125 treatment failed to diminish oxaliplatin/TRAIL-induced apoptosis in HT29 cells after Bcl-xL silencing ( Figure 5D ), suggesting that Bcl-xL is one specific target for JNK. As shown in Figure 5E , pretreatment with SP600125 highly reduced the level of Bcl-xL phosphorylation in HT29 cells upon oxaliplatin stimulation. In addition, JNK silencing reduced the amount of S62-phosphorylated Bcl-xL after oxaliplatin and oxaliplatin/TRAIL treatment in both cell lines ( Figure 5F ). These data provide strong experimental evidence that oxaliplatin-induced Bcl-xL phosphorylation requires JNK activation.
Bcl-xL Phosphorylation Is Responsible for Decreased Anti-Apoptotic Activity
To evaluate the role of Bcl-xL phosphorylation on its own anti-apoptotic activity, we established HT29-derived cell lines stably overexpressing wild-type Bcl-xL (HT29-BclxL.WT), Ser62/Asp phospho-mimic Bcl-xL mutant (HT29-Bcl-xL.S62D), Ser62/Ala phospho-defective Bcl-xL mutant (HT29-Bcl-xL.S62A), or the corresponding empty vector (HT29-EV). WT and S62D Bcl-xL proteins were overexpressed to a similar extent and S62A Bcl-xL protein to a lower level (ϳ40% less than WT and S62D Bcl-xL) ( Figure  6A ). Only Bcl-xL.S62D was recognized by the phospho-specific anti-Bcl-xL antibody ( Figure 6A ). As expected, overexpression of the WT Bcl-xL completely prevented oxaliplatin/ 290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347   290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345 346 347 348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404  405   348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404 TRAIL-induced apoptosis ( Figure 6B ), confirming that it largely relies on the mitochondrial pathway. Interestingly, ectopic expression of the phospho-mimic Bcl-xL S62D enhanced apoptosis induced by TRAIL alone and in combination with oxaliplatin, whereas HT29-Bcl-xL.S62A cells were clearly more resistant to oxaliplatin/TRAIL combination. Because Bcl-xL has been shown to inhibit apoptosis by interacting with Bax 16 and/or Bak, 17 we next tested whether combined treatments, through Bcl-xL phosphorylation, may alter their interactions with Bcl-xL. An interaction between Bcl-xL and Bax was detected in control and TRAIL-treated cells ( Figure 6C, lanes 1 and 3) . This interaction was reduced significantly after oxaliplatin treatment, independently of TRAIL stimulation (lanes 2 and 4) . On the other hand, no significant interaction was detected between Bcl-xL and Bak in both cell lines ( Figure 6C ). Moreover, phospho-mimic Bcl-xL (S62D) showed a weaker interaction with Bax in control cells, as compared with the WT Bcl-xL ( Figure 6D , lanes 5 and 9). Furthermore, although Bcl-xL/Bax heterodimers were maintained upon treatment in HT29-BclxL.WT ( Figure 6D , lanes 6 -8), this interaction was impaired in the presence of oxaliplatin in HT29-Bcl-xL.S62D ( Figure  6D , lanes 10 and 12). These observations were confirmed in reciprocal anti-Bax immunoprecipitation (Supplementary Figure 5) . The lack of interaction between Bcl-xL and Bak was confirmed in HT29.EV, HT29.WT, and HT29-BclxL.S62D cells (Supplementary Figure 6) , suggesting that the role of Bak regarding oxaliplatin/TRAIL-induced apoptosis is not related to Bcl-xL/Bak interaction. We next sought to determine the activation status of Bax released from Bcl-xL/Bax heterodimers by immunoprecipitation experiments with the anti-Bax 6A7 antibody, which specifically recognizes active Bax. 18 Bax was activated exclusively with the combined treatment in HT29.EV cells ( Figure  6E , lane 4), but not in HT29-Bcl-xL.WT (lane 8). In agreement with the hypothesis that Bcl-xL phosphorylation prevents Bax sequestration, Bax activation was detected after both TRAIL and oxaliplatin/TRAIL treatments in HT29-BclxL.S62D cells ( Figure 6E, lanes 11 and 12) . Moreover, as shown by co-immunoprecipitation, Bak only interacted with active Bax in HT29-EV cells treated with the oxaliplatin/ TRAIL combination ( Figure 6F, lane 4) or HT29-BclxL.S62D cells treated with TRAIL alone irrespective of oxaliplatin pretreatment ( Figure 6F, lanes 11 and 12) . Bax/Bak interaction was dependent entirely on Bax activation because Bak was immunoprecipitated only in cell extracts corresponding to active Bax (Supplementary Figure 7, lanes 4, 11,  and 12 ). These results indicate that oxaliplatin primes mitochondrial activation by inhibiting Bcl-xL-induced Bax sequestration, thus allowing Bax/Bak interaction upon apoptosis engagement.
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Discussion
The molecular basis of resistance to TRAIL-induced cytotoxicity is complex and multifactorial. 6, 19 However, this resistance can be overcome by combining TRAIL with cytotoxic agents. 9,10 Accordingly, we previously showed that oxaliplatin enhances TRAIL cytotoxicity in a large panel of colon cancer cell lines. 12 The sensitizing effects of chemotherapeutic drugs to TRAIL-induced apoptosis have been attributed to 3 main molecular events: (1) up-regulation of TRAIL death receptors DR4/DR5, 20 (2) enhancement of death-inducing signaling complex formation/function, 21 and/or (3) alteration of the expression level of pro-apoptotic/anti-apoptotic proteins. 22 We previously reported that oxaliplatin had no effect on TRAIL DRs cell surface expression in both HT29 and V9P cells, 12 arguing against the first possibility. The contribution of DR up-regulation remains a matter of debate. 23 Despite functional expression of DR4/DR5 TRAIL receptors, 19 a significant proportion of cultured malignant cells remain refractory to the cytotoxic effect of recombinant soluble TRAIL. In agreement with this observation, caspase-9 silencing, but not caspase-8 silencing, abrogated oxaliplatin/TRAIL-induced cell death, arguing against the possible involvement of membrane-related regulatory events including death-inducing signaling complex formation/function enhancement. On the contrary, oxaliplatin-induced sensitization to TRAIL required activation of the mitochondrial pathway, allowing a caspase-dependent feedback loop. These results are in agreement with data showing that caspase-9 can act as a feedback loop by cleaving caspase-8 to amplify the apoptotic process. 24 Further supporting this conclusion is the demonstration that Bax and Bak inhibition, or Bcl-xL overexpression, abrogated oxaliplatin/TRAIL-induced cell death. These observations clearly indicate that HT29 and V9P cancer cells behave as type II cells in which DRinduced apoptosis is controlled mainly by anti-apoptotic Bcl-2 family proteins. 6, 25 Interestingly, although Mcl-1, Bcl-2, or Bcl-xL expression levels were unaffected by oxaliplatin, a partial Bcl-xL phosphorylation was induced in both cell lines. Our data show Bcl-xL phosphorylation in response to a DNA-damaging agent. This finding is in contrast with previous reports suggesting that Bcl-xL phosphorylation is a specific consequence of antimitotic agents, 7, 14 explaining, in part, their ability to induce cellcycle arrest. 26 Interestingly, we previously showed that oxaliplatin treatment resulted in HT29 and V9P cell-cycle arrest. 27 This finding could explain why oxaliplatin can promote Bcl-xL phosphorylation.
Bcl-xL phosphorylation has been attributed to the activation of several kinases including JNK. 8, 26 On the one hand, Mucha et al 28 observed that JNK inhibition sensitizes hepatocellular carcinoma cells to TRAIL, but other groups have shown that JNK activation sensitizes hepatocellular carcinoma and breast cancer cells to TRAIL-induced apoptosis. 29, 30 Our results would rather support the second conclusion because apoptosis induced by oxaliplatin/TRAIL combination was strongly suppressed by JNK inhibition or knockdown. Several studies have focused on the implication of JNK activation in apoptosis induced by the mitochondrial pathway. It has been reported that JNK was required for stress-induced release of cytochrome c from mitochondria into the cytosol. 31 An-other study suggested that activated JNK might translocate to mitochondria and associate with Bcl-xL in response to cellular stress. 32 It also was reported that activation of JNK signaled mitochondrial translocation of Bax and Bcl-2 phosphorylation, resulting in mitochondrial apoptotic cell death. 33 In line with these findings, we show here that oxaliplatin-mediated Bcl-xL phosphorylation was dependent on JNK activation as shown by the use of JNK inhibitors or by JNK siRNA.
Overexpression of a S62 phospho-defective or phosphomimetic form of Bcl-xL provided strong support to our findings that JNK-induced Bcl-xL phosphorylation accounts for the restoration of the mitochondrial program and sensitivity to TRAIL-induced apoptosis, recapitulating the effect of oxaliplatin in these cells. It is worth mentioning that several reports already proposed the hypothesis that Bcl-xL anti-apoptotic function may be more critically related to its phosphorylation status than to its expression level. 7, 34 Of note, it was surprising to observe that cells overexpressing phospho-defective Bcl-xL were less resistant to oxaliplatin/TRAIL combination than those expressing the WT protein. This observation could be explained in part by the fact that phospho-defective Bcl-xL mutant was less overexpressed (ϳ40%) than WT Bcl-xL.
Bcl-xL protects cells from programmed cell death by dimerizing with and sequestering Bax 16 and Bak. 17 The finding that oxaliplatin-induced Bcl-xL phosphorylation compromises its ability to interact with Bax, as shown by co-immunoprecipitation analysis, accounts on its own for the restoration of TRAIL sensitivity in these cells. Moreover, these experiments showed that the phospho-mimic Bcl-xL mutant was unable to bind Bax even at basal conditions. Of note, and as previously shown, 27 despite its ability to induce Bcl-xL phosphorylation and Bax release, oxaliplatin alone was unable to induce apoptosis, indicating that additional events are required to engage the apoptotic program. Indeed, Bax translocation to mitochondria appears to be essential for Bax activation and apoptosis. 18, 35, 36 Oxaliplatin was unable to induce Bax conformational changes on its own, probably explaining, at least in part, its inefficiency in inducing apoptosis. The fact that Bax conformational changes occur only when oxaliplatin and TRAIL are combined suggests that in addition to its release from Bcl-xL, Bax activation requires additional events related to TRAIL/DR signaling. This hypothesis is supported by the observation that TRAIL alone induces Bax activation in HT29-Bcl-xL.S62D cells because Bax is no more sequestered by Bcl-xL because of its phosphorylation at the S62 site. Bax release from Bcl-xL therefore may represent the first step leading to Bax insertion into the mitochondrial membrane. Bax conformational changes are required for mitochondrial membrane permeabilization. The molecular mechanisms for Bax activation are not completely known but the involvement of the BH3-only protein Bid or RASSF1A has been proposed to play a substantial role. 18, 36, 37 Among these, Bid is probably the best-studied activator of Bax. In fact, Eskes et al 36 showed that Bid was able to induce Bax conformational change leading to the exposure of its N-terminal domain, allowing Bax integration in the outer mitochondrial membrane. In our experimental conditions, Bid is probably a good candidate because we have shown its cleavage upon TRAIL treatment. However, further experiments are needed to elucidate its involvement and we cannot exclude the possibility that other proteins, including RASSF1A, may take part in this process. Proposed mechanism for oxaliplatin-sensitizing effect to TRAIL. (A) TRAIL alone fails to reach a critical threshold to induce apoptosis because of its incapacity to overcome mitochondrial blockage. If cells are pretreated with oxaliplatin, (B) Bcl-xL is phosphorylated in a JNKdependent manner and Bax is released, driving mitochondrial signaling beyond a level compatible with cell death, causing cytochrome c release and caspase-9 activation. Caspase-9 on its turn activates caspase-8 through the feedback loop, leading to death-signaling amplification.
Importantly, although Bcl-xL is unable to sequester Bak directly (as shown by our immunoprecipitation experiments), its anti-apoptotic activity respective to Bak itself may result from its ability to sequester Bax.
Taken together, our results unveil a novel molecular signaling mechanism explaining how a DNA-damaging agent, such as oxaliplatin, synergizes with TRAIL to restore apoptosis in resistant colon cancer cell lines ( Figure  7) . Inactivating Bcl-xL represents a good opportunity to restore sensitivity to apoptosis. Given the fact that oxaliplatin is a commonly used chemotherapeutic drug for colon cancers, and that TRAIL currently is undergoing clinical testing, this drug combination has an excellent translational potential and should be considered for clinical development. 
Supplementary Material
Cell fractionation
Mitochondrial and cytosolic fractions were prepared according to manufacturer's instructions (Pierce Biotechnology). Briefly, 2x10 7 cells were washed with PBS and then incubated with 0.5 ml of mitochondrial isolation reagent A on ice for 10 min. The cells were then lysed using a Dounce homogenizer by 20 strokes of the pestle. The lysate was transferred to a centrifuge tube, the volume adjusted to 0.7 ml, and then 0.35 ml of 3X-concentrated mitochondrial isolation reagent B was added. The sample was centrifugated at 700 g for 10 min to pellet the nuclei and the supernatant was centrifugated at 12,000 g for 15 min to obtain the cytosolic fraction in the supernatant and a mitochondrial pellet which was resuspended in storage buffer. Equal amounts of proteins were subjected to electrophoresis and immunoblot analysis as described above.
Phosphatase treatment
Cells were collected by scraping and lysed during 30 minutes at 4°C in RIPA lysis buffer supplemented with protease inhibitor cocktail (Santa Cruz Biotechnology). Lysates were clarified by centrifugation at 14,000 rpm for 15 minutes at 4°C, and divided into two equal aliquots. One aliquot was treated for 30 minutes at 37°C with 10 units of Calf Alkaline Phosphatase (Roche diagnostics) and one aliquot was mock-treated. Products were analyzed by immunobloting.
Small interfering RNA transfection
Small interfering RNA (siRNA) pool consisting of four siRNAs specific for each protein (ON- 
Construction of the Bcl-xL phosphorylation mutant
Substitution of serine 62 to asparagine (S62D) or alanine (S62A) into the pMIGR-BclXL-GFP retroviral plasmid was performed by PCR using the following specific oligonucleotides 
Retrovirus production and cell transduction
Generation of retroviruses has been previously described (40). HT29 cells were transduced for 16 hours with viral supernatants containing polybrene (8 mg/ml), washed in phosphatebuffered saline, and cultured in complete medium. After transduction, GFP-positive cells were sorted using BD FACS vantage cell sorter.
Immunoprecipitation
Immunoprecipitation (IP) was carried out using the ExactaCruz product (SantaCruz were analyzed by western blot using appropriate primary antibodies and the secondary antibodies supplied by the ExactaCruz product.
Statistical analysis
All the data are summarized as mean ±SEM of at least three separate experiments.
Student's t-test was used to compare experimental with control groups. A P value < 0.05 was considered statistically significant. 
